Clinical Research Papers:

Elevated expression of RNA methyltransferase BCDIN3D predicts poor prognosis in breast cancer

Ling Yao, Yayun Chi, Xin Hu, Shan Li, Feng Qiao, Jong Wu and Zhi-Ming Shao _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:53895-53902. https://doi.org/10.18632/oncotarget.9656

Metrics: PDF 953 views  |   HTML 1350 views  |   ?  


Ling Yao1,*, Yayun Chi1,*, Xin Hu1,*, Shan Li1, Feng Qiao1, Jong Wu1,2,3 and Zhi-Ming Shao1,2,3

1 Department of Breast Surgery, Fudan University, Shanghai Cancer Center and Cancer Institute, Shanghai, P.R. China

2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China

3 Institutes of Biomedical Science, Fudan University, Shanghai, P.R. China

* These authors have contributed equally to this work

Correspondence to:

Zhi-Ming Shao, email:

Jong Wu, email:

Keywords: BCDIN3D, breast cancer, TNBC

Received: October 12, 2015 Accepted: May 13, 2016 Published: May 28, 2016


Background: BCDIN3D is a member of the Bin3 methyl-transferase family that targets the 5’ mono-phosphate of nucleic acids. Although BCDIN3D has been shown to increase tumorigenic phenotypes and invasiveness in MDA-MB-231 cells, its the clinical implications in breast cancer remain unclear. Methods: We screened for BCDIN3D using tissue microarrays constructed from 250 patients who were histologically confirmed to have invasive ductal breast carcinoma at the Fudan University Shanghai Cancer Center. Results: The survival analysis by Kaplan-Meier and Cox regression showed that BCDIN3D expression level served as a prognostic factor for disease-free survival (P = 0.042). The prognostic value of BCDIN3D was most significant in triple-negative breast cancer (TNBC) patients (P = 0.007). Conclusions: BCDIN3D might serve as an important prognostic factor for TNBC patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9656